When the authorisation is suspended, withdrawn or not renewed, or when a decision to modify the authorisation makes this necessary, the holder of the early access authorisation referred to in Article L. 5121-12 will take all necessary steps, in particular with stockholders, to stop distributing the medicinal product. If this measure is not taken within a timeframe compatible with the interests of public health, the Agence nationale de sécurité du médicament et des produits de santé will take all appropriate measures.